{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T05:54:55Z","timestamp":1794462895821,"version":"4.9.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T00:00:00Z","timestamp":1710288000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T00:00:00Z","timestamp":1710288000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1038\/s41591-024-02893-z","type":"journal-article","created":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T07:12:19Z","timestamp":1710313939000},"page":"1320-1329","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":415,"title":["Intrathecal bivalent CAR T cells targeting EGFR and IL13R\u03b12 in recurrent glioblastoma: phase 1 trial interim results"],"prefix":"10.1038","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7117-0539","authenticated-orcid":false,"given":"Stephen J.","family":"Bagley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7274-811X","authenticated-orcid":false,"given":"Meghan","family":"Logun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph A.","family":"Fraietta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arati S.","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda J.","family":"Bagley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Nabavizadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danuta","family":"Jarocha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rene","family":"Martins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eileen","family":"Maloney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lester","family":"Lledo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carly","family":"Stein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Leskowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5115-1321","authenticated-orcid":false,"given":"Julie K.","family":"Jadlowsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon","family":"Christensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bike Su","family":"Oner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Plesa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Brennan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1719-3887","authenticated-orcid":false,"given":"Fang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusha","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Whitney","family":"Gladney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Barrett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4861-0898","authenticated-orcid":false,"given":"MacLean P.","family":"Nasrallah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2829-2167","authenticated-orcid":false,"given":"Wei-Ting","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2517-6075","authenticated-orcid":false,"given":"Guo-Li","family":"Ming","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8720-5310","authenticated-orcid":false,"given":"Hongjun","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2098-2251","authenticated-orcid":false,"given":"Donald L.","family":"Siegel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0241-3557","authenticated-orcid":false,"given":"Carl H.","family":"June","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1125-4060","authenticated-orcid":false,"given":"Elizabeth O.","family":"Hexner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zev A.","family":"Binder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8479-7314","authenticated-orcid":false,"given":"Donald M.","family":"O\u2019Rourke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,13]]},"reference":[{"key":"2893_CR1","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1093\/neuonc\/noaa106","volume":"22","author":"PY Wen","year":"2020","unstructured":"Wen, P. Y. et al. Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. Neuro Oncol. 22, 1073\u20131113 (2020).","journal-title":"Neuro Oncol."},{"key":"2893_CR2","doi-asserted-by":"publisher","first-page":"eaaa0984","DOI":"10.1126\/scitranslmed.aaa0984","volume":"9","author":"DM O\u2019Rourke","year":"2017","unstructured":"O\u2019Rourke, D. M. et al. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Sci. Transl. Med. 9, eaaa0984 (2017).","journal-title":"Sci. Transl. Med."},{"key":"2893_CR3","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1097\/CJI.0000000000000260","volume":"42","author":"SL Goff","year":"2019","unstructured":"Goff, S. L. et al. Pilot trial of adoptive transfer of chimeric antigen receptor-transduced T cells targeting EGFRvIII in patients with glioblastoma. J. Immunother. 42, 126\u2013135 (2019).","journal-title":"J. Immunother."},{"key":"2893_CR4","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1001\/jamaoncol.2017.0184","volume":"3","author":"N Ahmed","year":"2017","unstructured":"Ahmed, N. et al. HER2-specific chimeric antigen receptor-modified virus-specific T cells for progressive glioblastoma: a phase 1 dose-escalation trial. JAMA Oncol. 3, 1094\u20131101 (2017).","journal-title":"JAMA Oncol."},{"key":"2893_CR5","doi-asserted-by":"publisher","first-page":"4062","DOI":"10.1158\/1078-0432.CCR-15-0428","volume":"21","author":"CE Brown","year":"2015","unstructured":"Brown, C. E. et al. Bioactivity and safety of IL13R\u03b12-redirected chimeric antigen receptor CD8+ T cells in patients with recurrent glioblastoma. Clin. Cancer Res. 21, 4062\u20134072 (2015).","journal-title":"Clin. Cancer Res."},{"key":"2893_CR6","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1056\/NEJMoa1610497","volume":"375","author":"CE Brown","year":"2016","unstructured":"Brown, C. E. et al. Regression of glioblastoma after chimeric antigen receptor T-cell therapy. N. Engl. J. Med. 375, 2561\u20132569 (2016).","journal-title":"N. Engl. J. Med."},{"key":"2893_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.694941","volume":"11","author":"Q Lin","year":"2021","unstructured":"Lin, Q. et al. First-in-human trial of EphA2-redirected CAR T-cells in patients with recurrent glioblastoma: a preliminary report of three cases at the starting dose. Front. Oncol. 11, 694941 (2021).","journal-title":"Front. Oncol."},{"key":"2893_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-022-01711-9","volume":"22","author":"Z Liu","year":"2023","unstructured":"Liu, Z. et al. Safety and antitumor activity of GD2-specific 4SCAR-T cells in patients with glioblastoma. Mol. Cancer 22, 3 (2023).","journal-title":"Mol. Cancer"},{"key":"2893_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.669071","volume":"11","author":"JS Durgin","year":"2021","unstructured":"Durgin, J. S. et al. Case Report: Prolonged survival following EGFRvIII CAR T cell treatment for recurrent glioblastoma. Front. Oncol. 11, 669071 (2021).","journal-title":"Front. Oncol."},{"key":"2893_CR10","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1158\/2159-8290.CD-20-1661","volume":"11","author":"D Alizadeh","year":"2021","unstructured":"Alizadeh, D. et al. IFN\u03b3 is critical for CAR T cell-mediated myeloid activation and induction of endogenous immunity. Cancer Discov. 11, 2248\u20132265 (2021).","journal-title":"Cancer Discov."},{"key":"2893_CR11","doi-asserted-by":"publisher","first-page":"eabe7378","DOI":"10.1126\/scitranslmed.abe7378","volume":"13","author":"JH Choe","year":"2021","unstructured":"Choe, J. H. et al. SynNotch-CAR T cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma. Sci. Transl. Med. 13, eabe7378 (2021).","journal-title":"Sci. Transl. Med."},{"key":"2893_CR12","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1093\/neuonc\/nox182","volume":"20","author":"K Bielamowicz","year":"2018","unstructured":"Bielamowicz, K. et al. Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma. Neuro Oncol. 20, 506\u2013518 (2018).","journal-title":"Neuro Oncol."},{"key":"2893_CR13","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.ymthe.2022.05.011","volume":"30","author":"Y Yin","year":"2022","unstructured":"Yin, Y. et al. Locally secreted BiTEs complement CAR T cells by enhancing killing of antigen heterogeneous solid tumors. Mol. Ther. 30, 2537\u20132553 (2022).","journal-title":"Mol. Ther."},{"key":"2893_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.664236","volume":"11","author":"R Thokala","year":"2021","unstructured":"Thokala, R. et al. High-affinity chimeric antigen receptor with cross-reactive scFv to clinically relevant EGFR oncogenic isoforms. Front. Oncol. 11, 664236 (2021).","journal-title":"Front. Oncol."},{"key":"2893_CR15","doi-asserted-by":"publisher","first-page":"2924","DOI":"10.1158\/0008-5472.CAN-11-3898","volume":"72","author":"HK Gan","year":"2012","unstructured":"Gan, H. K., Burgess, A. W., Clayton, A. H. & Scott, A. M. Targeting of a conformationally exposed, tumor-specific epitope of EGFR as a strategy for cancer therapy. Cancer Res. 72, 2924\u20132930 (2012).","journal-title":"Cancer Res."},{"key":"2893_CR16","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1073\/pnas.232686499","volume":"100","author":"AA Jungbluth","year":"2003","unstructured":"Jungbluth, A. A. et al. A monoclonal antibody recognizing human cancers with amplification\/overexpression of the human epidermal growth factor receptor. Proc. Natl Acad. Sci. USA 100, 639\u2013644 (2003).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2893_CR17","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1158\/1535-7163.MCT-14-0820","volume":"14","author":"EB Reilly","year":"2015","unstructured":"Reilly, E. B. et al. Characterization of ABT-806, a humanized tumor-specific anti-EGFR monoclonal antibody. Mol. Cancer Ther. 14, 1141\u20131151 (2015).","journal-title":"Mol. Cancer Ther."},{"key":"2893_CR18","doi-asserted-by":"crossref","unstructured":"Yin, Y. et al. Checkpoint blockade reverses anergy in IL13R\u03b12 humanized scFv based CAR T cells to treat murine and canine gliomas. Mol. Ther. Oncolytics 11, 20\u201338 (2018).","DOI":"10.1016\/j.omto.2018.08.002"},{"key":"2893_CR19","doi-asserted-by":"publisher","first-page":"3259","DOI":"10.1158\/1078-0432.CCR-18-3034","volume":"25","author":"AB Lassman","year":"2019","unstructured":"Lassman, A. B. et al. Comparison of biomarker assays for EGFR: implications for precision medicine in patients with glioblastoma. Clin. Cancer Res. 25, 3259\u20133265 (2019).","journal-title":"Clin. Cancer Res."},{"key":"2893_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-01392-9","volume":"8","author":"JP Newman","year":"2017","unstructured":"Newman, J. P. et al. Interleukin-13 receptor alpha 2 cooperates with EGFRvIII signaling to promote glioblastoma multiforme. Nat. Commun. 8, 1913 (2017).","journal-title":"Nat. Commun."},{"key":"2893_CR21","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s13311-016-0507-6","volume":"14","author":"BM Ellingson","year":"2017","unstructured":"Ellingson, B. M., Wen, P. Y. & Cloughesy, T. F. Modified criteria for radiographic response assessment in glioblastoma clinical trials. Neurotherapeutics 14, 307\u2013320 (2017).","journal-title":"Neurotherapeutics"},{"key":"2893_CR22","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1038\/s41591-023-02276-w","volume":"29","author":"J Mahdi","year":"2023","unstructured":"Mahdi, J. et al. Tumor inflammation-associated neurotoxicity. Nat. Med. 29, 803\u2013810 (2023).","journal-title":"Nat. Med."},{"key":"2893_CR23","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","volume":"20","author":"KM Cappell","year":"2023","unstructured":"Cappell, K. M. & Kochenderfer, J. N. Long-term outcomes following CAR T cell therapy: what we know so far. Nat. Rev. Clin. Oncol. 20, 359\u2013371 (2023).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2893_CR24","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","volume":"371","author":"SL Maude","year":"2014","unstructured":"Maude, S. L. et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 371, 1507\u20131517 (2014).","journal-title":"N. Engl. J. Med."},{"key":"2893_CR25","doi-asserted-by":"publisher","first-page":"6081","DOI":"10.1016\/j.cell.2021.11.016","volume":"184","author":"CR Good","year":"2021","unstructured":"Good, C. R. et al. An NK-like CAR T cell transition in CAR T cell dysfunction. Cell 184, 6081\u20136100 (2021).","journal-title":"Cell"},{"key":"2893_CR26","doi-asserted-by":"publisher","first-page":"3978","DOI":"10.1200\/JCO.21.01992","volume":"39","author":"BD Santomasso","year":"2021","unstructured":"Santomasso, B. D. et al. Management of immune-related adverse events in patients treated with chimeric antigen receptor T-cell therapy: ASCO guideline. J. Clin. Oncol. 39, 3978\u20133992 (2021).","journal-title":"J. Clin. Oncol."},{"key":"2893_CR27","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1038\/s41409-020-01156-y","volume":"56","author":"I Danylesko","year":"2021","unstructured":"Danylesko, I. et al. Immune imitation of tumor progression after anti-CD19 chimeric antigen receptor T cells treatment in aggressive B-cell lymphoma. Bone Marrow Transplant. 56, 1134\u20131143 (2021).","journal-title":"Bone Marrow Transplant."},{"key":"2893_CR28","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1038\/s41586-022-04489-4","volume":"603","author":"RG Majzner","year":"2022","unstructured":"Majzner, R. G. et al. GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas. Nature 603, 934\u2013941 (2022).","journal-title":"Nature"},{"key":"2893_CR29","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1158\/2159-8290.CD-22-0750","volume":"13","author":"NA Vitanza","year":"2023","unstructured":"Vitanza, N. A. et al. Intraventricular B7-H3 CAR T cells for diffuse intrinsic pontine glioma: preliminary first-in-human bioactivity and safety. Cancer Discov. 13, 114\u2013131 (2023).","journal-title":"Cancer Discov."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-02893-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-02893-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-02893-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T08:05:57Z","timestamp":1747641957000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-02893-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,13]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["2893"],"URL":"https:\/\/doi.org\/10.1038\/s41591-024-02893-z","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,13]]},"assertion":[{"value":"16 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2024","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"In the version of the article initially published an incorrect version of the\n                      \n                      was included. This has now been updated in the HTML version of the article.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.J.B. has received consulting fees from Telix, Servier, Kiyatec, Novocure and Bayer and has received research funding from Kite Pharma (a Gilead company) related to the submitted work and from Incyte, Novocure, GSK and Eli Lilly, all outside of the submitted work. J.A.F. is a member of the scientific advisory boards of Cartography Bio and Shennon Biotechnologies and has patents, royalties and other intellectual property (IP). W.G. is an employee of Kite Pharma (a Gilead company). D.B. is an employee of Kite Pharma (a Gilead company). D.L.S. holds founder\u2019s equity and has licensed IP to Verismo Therapeutics and Vetigenics and has IP licensing to Chimeric Therapeutics. C.H.J. and the University of Pennsylvania have patents pending or issued related to the use of gene modification in T cells for adoptive T cell therapy. C.H.J. is a co-founder of Tmunity (acquired by Kite Pharma, a Gilead company); is a scientific co-founder and holds equity in Capstan Therapeutics, Dispatch Biotherapeutics and BlueWhale Bio; serves on the board of AC Immune; is a scientific advisor to BlueSphereBio, Cabaletta, Carisma, Cartography, Cellares, Cellcarta, Celldex, Danaher, Decheng, ImmuneSensor, Kite Pharma, Poseida, Verismo, Viracta, Vittoria Biotherapeutics and WIRB-Copernicus group; and is an inventor on patents and\/or patent applications licensed to Novartis Institutes of Biomedical Research and Kite Pharma and may receive license revenue from such licenses. Z.A.B. has inventorship interest in IP owned by the University of Pennsylvania and has received royalties related to CAR T therapy in solid tumors. D.M.O. reports prior or active roles as consultant\/scientific advisory board member for Celldex Therapeutics, Prescient Therapeutics, Century Therapeutics and Chimeric Therapeutics and has received research funding from Celldex Therapeutics, Novartis, Tmunity Therapeutics and Gilead Sciences\/Kite Pharma. D.M.O is an inventor of IP (US patent numbers 7,625,558 and 6,417,168 and related families) and has received royalties related to targeted ErbB therapy in solid cancers previously licensed by the University of Pennsylvania. D.M.O is also an inventor on multiple patents related to CAR T cell therapy in solid tumors that have been licensed by the University of Pennsylvania and has received royalties from these license agreements. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}